Week 4 on GLP-1: what the science says about early progress

What did @ilosnewlife actually say?

Honestly, the transcript here is nearly unusable. The auto-generated captions appear to have completely failed, producing garbled English text that bears no relationship to what is actually being said in a Turkish-language video. What we do know comes from the caption itself: this creator just hit the four-week mark on what appears to be a GLP-1-related diet or medication protocol, and they are feeling good about it.

The caption reads, in translation, something close to: "Week 4 is complete. Hopefully my coming weeks will pass with the same ease and performance." That is a modest, experience-based statement. No wild claims about cure rates or dramatic weight numbers. Just a person four weeks into something, noting it is going reasonably well. The hashtag is simply "diyet" (diet in Turkish). There is not much to debunk here, but there is plenty worth contextualizing.

Does the science back this up?

Four weeks on a GLP-1 agonist is right at the edge of when people start to notice real changes, and the research largely supports that timeline. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that the most significant early appetite suppression from semaglutide tends to kick in between weeks two and eight as doses are titrated upward.

Feeling good at week four is actually consistent with what the data shows. Early weeks on GLP-1 medications often involve nausea, fatigue, and adjustment side effects. If someone is reporting ease at week four, that could mean one of two things: their titration schedule has been gradual enough to avoid the worst side effects, or they are among the roughly 30 to 40 percent of users who tolerate these medications with minimal GI disruption from the start (Davies et al., 2021, Lancet). Neither is surprising. What would be worth flagging is if someone at week four claimed dramatic, sustained weight loss, since most of the measurable body weight changes in clinical trials accumulate over months, not four weeks.

What did they get wrong (or right)?

Credit where it is due: this creator is not overclaiming. They are not saying they lost 20 kilograms, they are not telling followers to take a specific dose, and they are not positioning GLP-1 medication as a cure for anything. That restraint is genuinely rarer than it should be in this content category.

The caption's phrase about "the same performance" is slightly worth watching. On GLP-1 medications, weeks four through eight are often still in dose titration, meaning the experience can shift considerably. Performance at week four does not predict performance at week eight or week twelve. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) tracked liraglutide users and found that individual response variability is high, particularly in the first three months. Saying "hopefully the same ease continues" is fine as a wish, but followers should know that GLP-1 journeys are rarely linear. Side effects can return when doses increase, and plateaus are well documented.

What should you actually know?

If you are watching someone's four-week GLP-1 check-in and thinking about starting your own, here is what the research actually says you should expect.

• Weeks one through four are typically the lowest-dose phase. The real appetite suppression effects, and often the real side effects, intensify as doses increase in subsequent months.
• "Ease" at week four can be misleading as a benchmark. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide users experienced fluctuating tolerability across the full titration period, not a smooth linear improvement.
• GLP-1 medications are prescription drugs in most countries, including Turkey, and require medical supervision. A TikTok check-in is not a substitute for clinical monitoring of blood glucose, heart rate, and GI function.
• Weight outcomes on these medications depend heavily on consistent use, diet quality, and individual metabolic response. Social media check-ins capture mood and motivation, not the full clinical picture.

This creator seems to be doing things responsibly. That is worth acknowledging. But anyone using their experience as a template for their own expectations should know the science is more complicated than four weeks of feeling good suggests.